Monte Rosa Therapeutics, Inc. - Common Stock (NQ:GLUE)

17.29 -0.35 (-1.98%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2025 Add to My Watchlist

Price and Volume

Volume	626,544
Open	17.61
Bid (Size)	17.21 (200)
Ask (Size)	17.29 (200)
Prev. Close	17.64
Today's Range	16.81 - 17.61
52wk Range	3.500 - 19.17
Shares Outstanding	49,383,711
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations

December 16, 2025

From Monte Rosa Therapeutics, Inc.

Via GlobeNewswire

Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results

December 15, 2025

Conference call and webcast to be held at 8 a.m. ET on December 16, 2025

From Monte Rosa Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	+143.2%	+143.2%
1 Month	+8.1%	+8.1%
3 Month	+130.8%	+130.8%
6 Month	+275.9%	+275.9%
1 Year	+139.5%	+139.5%

More News

Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases

November 08, 2025

From Monte Rosa Therapeutics, Inc.

Via GlobeNewswire

Monte Rosa Therapeutics Stock Scores Biggest Gain In Nearly A Year On $5.7B Novartis Deal For Immune-Mediated Diseases ↗

September 15, 2025

Via Stocktwits

Monte Rosa Therapeutics Inc (NASDAQ:GLUE) Q3 2025 Earnings Beat Estimates, Stock Rises ↗

November 06, 2025

Via Chartmill

Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates

November 06, 2025

From Monte Rosa Therapeutics, Inc.

Via GlobeNewswire

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

November 03, 2025

From Monte Rosa Therapeutics, Inc.

Via GlobeNewswire

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases

October 24, 2025

From Monte Rosa Therapeutics, Inc.

Via GlobeNewswire

Dave & Buster's Entertainment Posts Downbeat Results, Joins Adtran Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

September 16, 2025

Via Benzinga

Why Webtoon Entertainment Shares Are Trading Higher By 48%; Here Are 20 Stocks Moving Premarket ↗

September 16, 2025

Via Benzinga

Here are the top movers in Monday's session. ↗

September 15, 2025

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 15, 2025

Via Benzinga

Which stocks are moving on Monday? ↗

September 15, 2025

Via Chartmill

Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments ↗

September 15, 2025

Via Benzinga

Monday's session: gap up and gap down stocks ↗

September 15, 2025

Via Chartmill

Monday's pre-market session: top gainers and losers ↗

September 15, 2025

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

September 15, 2025

Via Benzinga

Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases

September 15, 2025

From Monte Rosa Therapeutics, Inc.

Via GlobeNewswire

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

September 02, 2025

From Monte Rosa Therapeutics, Inc.

Via GlobeNewswire

Monte Rosa (GLUE) Q2 Revenue Jumps 394% ↗

August 07, 2025

Via The Motley Fool

Monte Rosa Therapeutics Inc (NASDAQ:GLUE) Q2 2025 Earnings: Revenue Surges, Loss Narrower Than Expected ↗

August 07, 2025

Via Chartmill

Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates

August 07, 2025

From Monte Rosa Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

July 22, 2025

Via Benzinga

Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases

July 21, 2025

From Monte Rosa Therapeutics, Inc.

Via GlobeNewswire

Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines

July 03, 2025

From Monte Rosa Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Monte Rosa Therapeutics, Inc. - Common Stock publicly traded?

Yes, Monte Rosa Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Monte Rosa Therapeutics, Inc. - Common Stock trade on?

Monte Rosa Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Monte Rosa Therapeutics, Inc. - Common Stock?

The ticker symbol for Monte Rosa Therapeutics, Inc. - Common Stock is GLUE on the Nasdaq Stock Market

What is the current price of Monte Rosa Therapeutics, Inc. - Common Stock?

The current price of Monte Rosa Therapeutics, Inc. - Common Stock is 17.29

When was Monte Rosa Therapeutics, Inc. - Common Stock last traded?

The last trade of Monte Rosa Therapeutics, Inc. - Common Stock was at 12/26/25 04:00 PM ET

What is the market capitalization of Monte Rosa Therapeutics, Inc. - Common Stock?

The market capitalization of Monte Rosa Therapeutics, Inc. - Common Stock is 853.84M

How many shares of Monte Rosa Therapeutics, Inc. - Common Stock are outstanding?

Monte Rosa Therapeutics, Inc. - Common Stock has 854M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.